Clinical Trial Update: Calizumab Combined With Bevacizumab and Capecitabine in the Treatment of Head and Neck Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating Calizumab with Bevacizumab and Capecitabine for head and neck squamous cell carcinoma is ongoing; status currently unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• Calizumab (Calizumab)
• Capecitabine (capecitabine)

Snippet

Sponsor: Second Affiliated Hospital of Guangzhou Medical University | Conditions: Head and Neck Squamous Cell Carcinoma | Phase 2 | Status: UNKNOWN